- Stocks
- Pharma & Healthcare
- Aurobindo Pharma
Aurobindo Pharma share price
NSE: AUROPHARMAPharma & HealthcareDrug Manufacturers - Specialty & Generic
Aurobindo Pharma at a glance
Aurobindo Pharma (NSE: AUROPHARMA) closed at ₹1,571.30 on 22 Oct 2026, down 0.01% on the day. With a market capitalisation of ₹92,688 Cr, it ranks 116th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 26× trailing earnings, against a return on equity of 9.2% in FY26. Over the past year the share price has risen 40.0%. Its 52-week range is ₹1,080.10 (24 Oct 2025) to ₹1,740.00 (24 Sep 2026); the last close is 9.7% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹9,106 Cr (+16.9% year on year) and net profit ₹1,034 Cr (+25.7%), on a consolidated basis. Promoters held 51.88% of the company as of 30 Jun 2026; 13.75% of promoter shares were pledged.
Key numbers
- Market cap
- ₹92,688 CrRank 116 on NSE
- P/E (trailing)
- 26×
- Price to book
- 2×FY26
- EPS (TTM)
- ₹64.00to Q1 FY27
- ROE
- 9.2%FY26
- ROCE
- 13.7%FY26
- Debt to equity
- 0.2FY26
- Net profit margin
- 10.4%FY26
- Book value / share
- ₹652.39FY26
- 52-week high
- ₹1,740.0024 Sep 2026
- 52-week low
- ₹1,080.1024 Oct 2025
- 1-year return
- +40.0%
- RSI (14-day)
- 32.3
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.01% | −5.5% | −8.5% | +2.5% | +40.0% |
Aurobindo Pharma quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹7,646 Cr | ₹7,893 Cr | ₹8,381 Cr | ₹7,792 Cr | ₹8,237 Cr | ₹8,605 Cr | ₹8,752 Cr | ₹9,106 Cr |
| Revenue YoY | +6.9% | +8.6% | +10.6% | +3.0% | +7.7% | +9.0% | +4.4% | +16.9% |
| Net profit | ₹817 Cr | ₹844 Cr | ₹935 Cr | ₹822 Cr | ₹846 Cr | ₹909 Cr | ₹923 Cr | ₹1,034 Cr |
| Net profit YoY | +8.7% | −10.5% | +1.6% | −10.6% | +3.7% | +7.8% | −1.3% | +25.7% |
| Net margin | 10.7% | 10.7% | 11.2% | 10.6% | 10.3% | 10.6% | 10.5% | 11.4% |
| EPS | ₹14.00 | ₹14.56 | ₹15.56 | ₹14.20 | ₹14.61 | ₹15.67 | ₹15.86 | ₹17.86 |
Aurobindo Pharma financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹24,775 Cr | ₹23,455 Cr | ₹24,855 Cr | ₹29,002 Cr | ₹31,724 Cr | — |
| Operating profit | ₹4,584 Cr | ₹3,532 Cr | ₹2,624 Cr | ₹4,589 Cr | ₹5,098 Cr | — |
| Net profit | ₹5,389 Cr | ₹2,678 Cr | ₹1,939 Cr | ₹3,186 Cr | ₹3,515 Cr | — |
| EPS (₹) | ₹91.00 | ₹45.00 | ₹33.00 | ₹54.00 | ₹60.00 | — |
| Cash from operations | ₹3,329 Cr | ₹5,016 Cr | ₹2,387 Cr | ₹2,435 Cr | ₹3,925 Cr | — |
| Total debt | ₹168 Cr | ₹249 Cr | ₹619 Cr | ₹2,135 Cr | ₹1,562 Cr | ₹803 Cr |
| Shareholders' equity | ₹21,930 Cr | ₹24,576 Cr | ₹26,840 Cr | ₹29,843 Cr | ₹32,653 Cr | ₹37,891 Cr |
Aurobindo Pharma shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.88% |
| Foreign institutions | 15.33% | 14.37% | 14.21% | 13.94% | 15.24% | 16.38% |
| Domestic institutions | 26.23% | 26.93% | 27.60% | 27.68% | 25.87% | 25.10% |
| Non-institutions | 6.61% | 6.87% | 6.38% | 6.55% | 7.08% | 6.64% |
| Promoter shares pledged | 16.92% | 17.08% | 17.50% | 17.50% | 23.65% | 13.75% |
Aurobindo Pharma vs peers
The listed Pharma & Healthcare companies nearest to Aurobindo Pharma by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| LAURUSLABSLaurus Labs | ₹2,010.10 | +0.02% | +129.8% | ₹1,08,185 Cr | 121.7 | 8.0% |
| CIPLACipla | ₹1,312.60 | +0.08% | −15.2% | ₹1,07,516 Cr | 27.3 | 11.3% |
| DRREDDYDr. Reddy's Laboratories | ₹1,236.20 | −0.26% | +0.0% | ₹1,03,416 Cr | 25 | 11.1% |
| MANKINDMankind Pharma | ₹2,236.60 | −1.69% | −8.1% | ₹93,981 Cr | 48.4 | 11.7% |
| AUROPHARMAAurobindo Pharma | ₹1,571.30 | −0.01% | +40.0% | ₹92,688 Cr | 26 | 9.2% |
| LUPINLupin | ₹1,929.60 | −0.64% | −0.3% | ₹87,880 Cr | 16.6 | 23.8% |
| MAXHEALTHMax Healthcare Institute | ₹804.80 | −1.54% | −30.6% | ₹79,514 Cr | 54.6 | 13.4% |
Ask anything about Aurobindo Pharma
Pivot answers on the live chart with evidence you can check, and tests strategies against AUROPHARMA's own history. Try: “Why has AUROPHARMA moved over the last three months?” · “Backtest a 50-day moving-average crossover on AUROPHARMA over five years” · “Compare AUROPHARMA with LAURUSLABS on margins and valuation”
Frequently asked questions about Aurobindo Pharma
What is the share price of Aurobindo Pharma today?
Aurobindo Pharma (NSE: AUROPHARMA) last closed at ₹1,571.30 on 22 Oct 2026. Its 52-week high is ₹1,740.00 and its 52-week low is ₹1,080.10.
What is the market cap of Aurobindo Pharma?
Aurobindo Pharma's market capitalisation is ₹92,688 Cr (₹92,688 Cr) at the 22 Oct 2026 close, ranking 116th among the NSE companies Pivot tracks.
What is the P/E ratio of Aurobindo Pharma?
Aurobindo Pharma trades at a trailing P/E of 26. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 48.4.
What is the ROE and ROCE of Aurobindo Pharma?
Return on equity was 9.2% in FY26 and return on capital employed was 13.7% in FY26 (consolidated figures).
Is Aurobindo Pharma a debt-free company?
No. Aurobindo Pharma's debt-to-equity ratio was 0.2 in FY26, with total debt of ₹803 Cr.
What were Aurobindo Pharma's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Aurobindo Pharma reported revenue of ₹9,106 Cr, +16.9% year on year, and net profit of ₹1,034 Cr, +25.7% year on year.
How has Aurobindo Pharma stock performed over the last year?
Aurobindo Pharma's share price has risen 40.0% over the past year, +2.5% over three months and −8.5% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Aurobindo Pharma?
As of 30 Jun 2026: promoters 51.88%, foreign institutions 16.38%, domestic institutions 25.10%, non-institutions 6.64%. 13.75% of promoter shares were pledged.
Who are Aurobindo Pharma's competitors?
The listed Pharma & Healthcare companies closest to Aurobindo Pharma by market cap are Laurus Labs, Cipla, Dr. Reddy's Laboratories, Mankind Pharma, Lupin and Max Healthcare Institute.
Is Aurobindo Pharma a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Aurobindo Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on AUROPHARMA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text